Psoriasis

In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.

A JAMA Dermatology study shows that adherence to a Mediterranean diet high in anti-inflammatory nutrients may lessen psoriasis severity.

The prevalence of psoriatic arthritis in patients with psoriasis worldwide appears to be around 20 percent, shows a meta-analysis published in JAAD.

Longer, more in-depth consultations with dermatologists, nursing staff, physician assistants could improve outcomes in psoriasis.

Obesity appears to be an important independent risk factor for children with psoriasis who go on to develop cormorbidities, such as hypertension and diabetes, a study shows.

As dermatologists become increasingly aware of comorbidities associated with psoriasis, questions of associated malignancy risk remain. Dr. Megan Noe emphasizes the need for skin cancer checks.

Patients with psoriasis have a higher risk of developing new onset diabetes mellitus. It’s a risk that’s been described as statistically significant. So, in this article, we examine dermatologic care for diabetic foot infections.

Newer biologics that target interleukin (IL)-17 and IL-23 are changing the paradigm for psoriasis treatment, report physicians.

The August issue of Dermatology Times includes a supplement edition that focuses on a patient-centered approach in psoriasis management, including an article on the importance of longer consults in the doctor's office and recommendations for individualized therapy. Read more here.  

For psoriasis in difficult locations including the scalp, palms and soles, guselkumab outperformed adalimumab and placebo, shows a study published online in JAMA Dermatology.

Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery.

A new methotrexate usage survey shows that most patients with arthritis do not discuss medication modification strategies with their doctors.

Reproductive age women with psoriasis could benefit from an endocrinologist or obstetrician referral before starting systemic therapy.

Gestational diabetes, gestational hypertension and pre-eclampsia are higher in women with psoriasis or psoriatic arthritis.

A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.

This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.

Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.

There are two important reasons why physicians should consider the role of diet in triggering psoriasis flares, says a leading expert.

Diet can affect skin conditions including acne, atopic dermatitis, psoriasis and rosacea. In a review that focuses on these four conditions, plus aging, Rajani Katta, M.D., and Mary Jo Kramer, B.S., writing in Skin Therapy Letter, highlight trigger foods that should be avoided.

Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.

The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD. 

Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.

UCB’s Cimzia (certolizumab pegol) was recommended for approval by the European Committee for Medicinal Products (CHMP) for the treatment of adult patients with moderate-to-severe plaque psoriasis.